ClinicalTrialsFinder

Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation Clinical Trials in Shanghai, Shanghai Municipality

1 recruitingShanghai, Shanghai Municipality, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University40 enrolled1 locationNCT06970353